One example is the head-to-head comparison of aminoglutethimide (aromatase inhibition: 90%) and letrozole (aromatase inhibition: >99%) showing clearly superiority of letrozole in the setting of advanced breast cancer (Gershanovich et al, 1998). This evidence concerns the gene CYP19A1 and breast carcinoma.